Loading...
•
Dec 31, 2021
Humana Q4 2021 Earnings Report
Humana reported a GAAP loss per common share of $0.11 and an adjusted EPS of $1.24 for Q4 2021. The company provided FY 2022 EPS guidance of at least $23.08 on a GAAP basis and at least $24.00 on an adjusted basis.
Key Takeaways
Humana reported a loss per common share of $0.11 on a GAAP basis and an adjusted EPS of $1.24 for the fourth quarter of 2021. The company's core operations remain strong, driven by its Medicare Advantage business and Healthcare Services lines. Humana commits to drive $1 billion of additional value for the enterprise through cost savings, productivity initiatives, and value acceleration from previous investments to create capacity to fund growth and investment in the Medicare Advantage business and further expansion of Healthcare Services capabilities.
Humana reported a 4Q21 GAAP loss per share of $0.11, with an adjusted EPS of $1.24.
The company's FY 2021 EPS was $22.67 on a GAAP basis and $20.64 on an adjusted basis.
Humana announced FY 2022 EPS guidance of at least $23.08 on a GAAP basis and at least $24.00 on an adjusted basis, which includes a $1.00 COVID-19 related headwind.
Humana is committed to driving $1 billion of additional value through cost savings and productivity initiatives.
Humana
Humana
Forward Guidance
Humana provided its GAAP and Adjusted EPS guidance for the year ending December 31, 2022 (FY 2022). Humana's GAAP and Adjusted EPS guidance contemplates an explicit COVID-19 related headwind of $1.00 per diluted common share.
Positive Outlook
- Humana expects improved membership growth.
- Humana anticipates further penetration in growing and maturing Healthcare Services businesses.
- Humana is increasing focus on productivity improvements.
- Humana aims to deliver on its long-term earnings target in 2023 and beyond.
- Humana commits to drive $1 billion of additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments.
Challenges Ahead
- Humana's GAAP and Adjusted EPS guidance contemplates an explicit COVID-19 related headwind of $1.00 per diluted common share.
- The company will be conservative regarding the timing and pace with which it adjusts its FY 2022 earnings guidance.
- Humana anticipates that it will experience certain one-time restructuring charges in FY 2022 that will impact its GAAP results.
- There is uncertainty regarding the impact of COVID-19 on Humana's future performance.
- The spread and impact of COVID-19 and additional variants, or actions taken to mitigate this spread, could have material and adverse effects on Humana’s ability to operate effectively.